Gamboa EC, Zúñiga MD

Idioma: Español
Referencias bibliográficas: 25
Paginas: 23-27
Archivo PDF: 395.54 Kb.

RESUMEN

Los tumores neuroendocrinos gástricos (TNEG) son neoplasias malignas de estirpe epitelial vinculadas al sistema APUD (Amine Precursor Uptake Descarboxilase) que se originan de las células similares a enterocromafines gástricas. Representan un 7-8% de las neoplasias neuroendocrinas del tracto gastrointestinal. Presentan características del sistema endocrino difuso y elementos neurales; de ahí el origen de su nombre. Históricamente también se han llamado tumores carcinoides, sin embargo, se reconoce este término como arcaico y ambiguo por lo que ha caído en desuso. Se ha presentado un incremento notable en el diagnóstico de los TNEG en las últimas décadas y la causa de este fenómeno no está clara aún. En los Estados Unidos, por ejemplo, en los últimos 35 años la incidencia de los TNEG ha aumentado 10 veces. De ahí la importancia de conocer acerca de estos tumores, ya que aunque no son las neoplasias gástricas más frecuentes, su diagnóstico ha aumentado considerablemente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Sundaresan S Kang A Merchant J. Pathophisiology of gastric NETs: Role of gastrin and menin. Current Gastroenterology. 2017; 19:32.

2. D’Adda T, Keller G Bordi C Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Investig. 1999; 79(6):671–677

3. Joo Young K Seung-Mo H Jae Y. Recent updates on grading and classification of neuroendocrine tumors. Annals of Diagnostic Pathology 29. 2017; 11–16.

4. Rindi G Petroni G Inzani F. 25 years of neuroendocrine neoplasms of the gastrointestinal tract. Endocr pathol. 2014; 25: 59-64.

5. Zhang L Ozao J Warner R et al. Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor. World J Surg 2011;35(8):1880.

6. Kidd M, Gustafsson B, Modlin IM. Gastric carcinoids (neuroendocrine neoplasms). Gastroenterol Clin North Am. 2013; 42: 381–397.

7. Thomas D. Long-term follow up of a large series of patientes with Type I gastric carcinoid tumors: data from a multicenter study. European Journal of Endocrinology. 2013; 168: 185–193.

8. Modlin IM Kidd M Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg. 2002; 168: 669–683.

9. Basuroy R Srirajaskanthan R Prachalias A et al. Review article: the investigation and management of gastric neuroendocrine tumors. Aliment Pharmacol Ther. 2014; 39:1071–1084.

10. Basuroy R Sarker D Quaglia A et al. Personalized medicine for gastroentero- pancreatic neuroendocrine tumors: a distant dream? Int J Endocr Oncol. 2015; 2(3):201–215.

11. Bodei L Kidd M Modlin IM et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2015;43(5):839–851.

12. Cavallaro L. The role of 68-GA-DOTATOC CTPET in surgical tactic for gastric neuroendocrine tumors treatment experience: A case report. International Journal of Surgery .2014;225-231.

13. Duk Jung Y. Gastric neuroendocrine tumor mimicking early gastric cancer. gastrointestinal endoscopy Journal. 2017;86 (4):741.

14. Modlin IM Lye KD Kidd MA. 50-year analysis of 562 gastric carcinoids: small tumor or larger problema? American Journal of Gastroenterology. 2004;99:23–32.

15. Corey B Chen H. Neuroendocrine Tumours of the Stomach. Surgical Clinics North America. 2017; 97: 333-343.

16. Cavalcoli F Zilli A Conte D Ciafardini C Massironi S. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? Scandinavian Journal of gastroenterology. 2015; 50: 1397-1403.

17. Gray K. Predicting Survival and Response to Treatment in Poorly-Differentiated Neuroendocrine Tumors of the Esophagus and Stomach. jam coll surg. 2017; 1072: 7515-7517

18. Cavallaro L. The role of 68-GA-DOTATOC CTPET in surgical tactic for gastric neuroendocrine tumors treatment experience: A case report. International Journal of Surgery. 2014; 225- 231

19. Chen WC Warner RRP Ward SC et al. Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience. Dig Dis Sci. 2015; 60: 996–1003.

20. Richards ML Gauger P Thompson NW et al. Regression of type II gastric carci- noids in multiple endocrine neoplasia type 1 patients with Zollinger- Ellison syndrome after surgical excision of all gastrinomas. World J Surg. 2004; 28(7): 652–658.

21. Gilligan CJ Lawton GP Tang LH et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995; 90(3): 338–352.

22. Rinke A Krug S. Neuroendocrine tumours- Medical therapy: biological. Best Practice & Research Clinical Endocrinology & Metabolism. 2016;30: 79-91

23. Pasricha G Parikshit P Nour D Dulabh K. Management of well-differentiated gastroenteropancreatic neuroendocrine tumors (GEPNETs): A review. Clin Ther. 2017; 39:2146–2157.

24. Holzheimer RG Mannick J. Surgical treatment: evidence– based and problem oriented. Zuckschwerdt. 2001.

25. Paprottka PM Hoffman RT Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90microspheres. Cardiovasc Intervent Radiol. 2012; 35:334–342.